论文部分内容阅读
目的探讨2型糖尿病患者应用厄贝沙坦治疗前后其血浆TXA2/PGI2的变化,并分析其与患者尿微量白蛋白水平之间的关系。方法研究中共收入112例2型糖尿病患者,随机分入对照组及治疗组,以ELISA法检测其血浆中TXA2与PGI2的水平,同时对研究对象的尿微量白蛋白水平进行检测,分析治疗前后患者尿微量白蛋白水平的变化。结果治疗组患者在接受4周厄贝沙坦治疗后其血浆TXA2水平(319.65±38.76)pg/mL显著低于治疗前(342.12±48.22)pg/mL(P<0.01),而PGI2水平(40.04±4.95)pg/mL则显著高于治疗前(32.13±4.47)pg/mL(P<0.01),治疗组患者尿微量白蛋白水平较治疗前有显著下降[治疗后(36.42±4.95)mg/Lv.s.治疗前(43.99±11.27)mg/L,P<0.01];对照组中患者的TXA2/PGI2及尿微量白蛋白水平在接受治疗前后差异无统计学意义。结论2型糖尿病患者接受厄贝沙坦治疗后血浆TXA2/PGI2水平产生变化,同时尿微量白蛋白水平下降,提示TXA2/PGI2可能参与糖尿病肾病发展过程,而厄贝沙坦则可能阻断此过程并产生肾保护作用。
Objective To investigate the changes of plasma TXA2 / PGI2 in patients with type 2 diabetes mellitus before and after irbesartan treatment and analyze its relationship with urinary albumin levels in patients. Methods A total of 112 Chinese patients with type 2 diabetes were enrolled and randomly divided into control group and treatment group. The levels of TXA2 and PGI2 in plasma were detected by ELISA, and the levels of urine microalbumin in the plasma were detected. Changes in urinary microalbumin levels. Results The plasma levels of TXA2 (319.65 ± 38.76) pg / mL after treatment with irbesartan in the treatment group were significantly lower than those before treatment (342.12 ± 48.22) pg / mL (P <0.01), while the PGI2 level ± 4.95) pg / mL was significantly higher than that before treatment (32.13 ± 4.47) pg / mL (P <0.01). The urinary albumin level in the treatment group was significantly lower than that before treatment [36.42 ± 4.95 mg / Lv.s. Before treatment (43.99 ± 11.27) mg / L, P <0.01]. The levels of TXA2 / PGI2 and urine microalbumin in the control group had no significant difference before and after treatment. Conclusions The changes of plasma TXA2 / PGI2 level and urine microalbumin level in type 2 diabetic patients receiving irbesartan treatment suggest that TXA2 / PGI2 may be involved in the development of diabetic nephropathy, while irbesartan may block this process And produce renal protection.